Abstract
The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM- 1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic inflammation- associated diseases, easily detectable in biological fluids. High TREM-1 expression in macrophages infiltrating human tumors and increased concentrations of soluble TREM-1 also correlate with aggressive tumor behavior and recurrence and are a relevant independent predictor of poor patient survival. Pharmacological inhibition of TREM-1 has proven effective in preclinical mouse models of infectious and non-infectious inflammatory disorders and malignancies, conferring survival advantages and protecting from organ damage or tumor growth by attenuating inflammatory responses. This review aims at providing a comprehensive overview of the state of the art on TREM-1 research. We review the literature addressing TREM-1 role in the amplification of myeloid cell inflammatory responses at pathologic sites and its relevance in the development, severity, and progression of inflammatory diseases and cancer. Furthermore, we discuss recent advances in the pharmacological use of TREM-1 inhibitors in mouse preclinical models, emphasizing their potential in new strategies for the treatment of acute and chronic inflammatory conditions and for therapeutic intervention in cancer. This information will be of value to investigators in the field of pharmacology, drawing attention to novel therapeutic opportunities to complement current treatment approaches.
Keywords: Innate immune cells, immunoregulatory receptors, triggering receptor expressed on myeloid cells, inflammation, inflammatory diseases, cancer, disease models, therapy.
Current Pharmaceutical Design
Title:Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Volume: 22 Issue: 41
Author(s): Maria Carla Bosco, Federica Raggi and Luigi Varesio
Affiliation:
Keywords: Innate immune cells, immunoregulatory receptors, triggering receptor expressed on myeloid cells, inflammation, inflammatory diseases, cancer, disease models, therapy.
Abstract: The triggering receptor expressed on myeloid cells (TREM)-1 is a member of the Ig-like immunoregulatory receptor family and a major amplifier of innate immune responses. TREM- 1 has been implicated in the development and perpetuation of a number of inflammatory disorders, and soluble TREM-1 levels are a clinically valuable diagnostic and prognostic biomarker in patients with sepsis and other types of acute and chronic inflammation- associated diseases, easily detectable in biological fluids. High TREM-1 expression in macrophages infiltrating human tumors and increased concentrations of soluble TREM-1 also correlate with aggressive tumor behavior and recurrence and are a relevant independent predictor of poor patient survival. Pharmacological inhibition of TREM-1 has proven effective in preclinical mouse models of infectious and non-infectious inflammatory disorders and malignancies, conferring survival advantages and protecting from organ damage or tumor growth by attenuating inflammatory responses. This review aims at providing a comprehensive overview of the state of the art on TREM-1 research. We review the literature addressing TREM-1 role in the amplification of myeloid cell inflammatory responses at pathologic sites and its relevance in the development, severity, and progression of inflammatory diseases and cancer. Furthermore, we discuss recent advances in the pharmacological use of TREM-1 inhibitors in mouse preclinical models, emphasizing their potential in new strategies for the treatment of acute and chronic inflammatory conditions and for therapeutic intervention in cancer. This information will be of value to investigators in the field of pharmacology, drawing attention to novel therapeutic opportunities to complement current treatment approaches.
Export Options
About this article
Cite this article as:
Bosco Carla Maria, Raggi Federica and Varesio Luigi, Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer, Current Pharmaceutical Design 2016; 22 (41) . https://dx.doi.org/10.2174/1381612822666160826110539
DOI https://dx.doi.org/10.2174/1381612822666160826110539 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Pharmacokinetic and Pharmacodynamic Aspects of Linezolid with Infection Outcome
Current Drug Metabolism Susceptibility of Periodontopathogenic and Cariogenic Bacteria to Defensins and Potential Therapeutic Use of Defensins in Oral Diseases
Current Pharmaceutical Design Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging A Brief Overview of Antimicrobial Peptides Containing Unnatural Amino Acids and Ligand-Based Approaches for Peptide Ligands
Current Topics in Medicinal Chemistry Effect of Immunoglobulin Therapy on Blood Viscosity and potential concerns of Thromboembolism, Especially in Patients with Acute Kawasaki Disease
Recent Patents on Cardiovascular Drug Discovery Therapeutic Modulation of Cytokines in Chronic Infectious Diseases
Current Pharmaceutical Design Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Current Pharmaceutical Biotechnology Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Synthesis and Antimicrobial Evaluation of (Z)-5-((3-phenyl-1H-pyrazol-4- yl)methylene)-2-thioxothiazolidin-4-one Derivatives
Medicinal Chemistry Ceftriaxone-Vancomycin Drug Toxicity Reduction by VRP 1020 in Mus musculus Mice
Current Clinical Pharmacology Multiple Drugs Causing Severe Anemia in Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Nutrition in Infancy
Current Pediatric Reviews Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology Anti-Pathogenic Efficacy and Molecular Targets of a Polyherbal Wound- Care Formulation (Herboheal) Against Staphylococcus aureus
Infectious Disorders - Drug Targets High-Level Aminoglycoside Resistance in Enterococcus Faecalis and Enterococcus Faecium; as a Serious Threat in Hospitals
Infectious Disorders - Drug Targets Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews